Increased KIF11/kinesin-5 expression offsets Alzheimer Aβ-mediated toxicity and cognitive dysfunction

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyloid-beta (Aβ) inhibits the kinesin motor protein KIF11, causing neuronal dysfunction linked to Alzheimer's disease (AD).
• This inhibition affects microtubule networks and receptor localization, potentially underlying cognitive deficits in AD.

Purpose of the Study:

• To investigate the therapeutic potential of KIF11 in mitigating Aβ-induced neuronal damage and cognitive decline in Alzheimer's disease.
• To explore the relationship between KIF11 expression, synaptic integrity, and cognitive performance in AD models and patients.

Main Methods:

• Overexpression of KIF11 in cultured neurons and hippocampal slices to assess rescue of Aβ-mediated defects.
• Utilizing the 5xFAD transgenic mouse model of AD to evaluate the effects of Kif11 overexpression on spatial learning.
• Analyzing KIF11 expression levels in post-mortem brain samples from AD patients with varying cognitive statuses.

Main Results:

• KIF11 overexpression reversed Aβ-induced decreases in dendritic spine density and improved long-term potentiation.
• Transgenic Kif11 overexpression prevented spatial learning deficits in the 5xFAD mouse model.
• Higher KIF11 expression in AD brains correlated with better cognitive performance and increased synaptic protein mRNA levels.

Conclusions:

• KIF11 acts as a critical target of Aβ toxicity, with its inhibition contributing to synaptic damage in Alzheimer's disease.
• Modulating KIF11 levels represents a promising therapeutic strategy for preserving synaptic function and cognitive abilities in AD.
• These findings integrate molecular, cellular, animal, and human data to establish KIF11's role in AD pathogenesis and potential as a therapeutic target.